XTLB
XTL Biopharmaceuticals
XTLB
XTLB
2 hedge funds and large institutions have $316K invested in XTL Biopharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
No buyers this quarter
Top Sellers
| 1 |
1
Morgan Stanley
New York
|
$54.7K |
| 2 |
2
UBS Group
Zurich,
Switzerland
|
$0 |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $261K | 198,888 | – | – |
|
|
2
Morgan Stanley
New York
| $54.7K | 41,771 | -1,200 | -3% |
|
|
3
UBS Group
Zurich,
Switzerland
| – | – | -300 | Closed |
|
|
CFGS
4
Concourse Financial Group Securities
Birmingham,
Alabama
| – | – | – | – |
|